SOAT1 and myeloproliferative disorder: Despite the unclear mechanism of ruxolitinib actions in targeting Jak/Stat signalling pathway, the drug has been repeatedly shown effective against myeloproliferative neoplasms and dramatically reduced the associated symptoms in patients3,42.